Clinical Trial Update: Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 study of recombinant Factor IX Fc fusion protein (rFIXFc) in participants with severe Hemophilia B completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFIXFc (recombinant Factor IX Fc fusion protein)

Snippet

Sponsor: Bioverativ Therapeutics Inc. | Conditions: Severe Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2014-09-04